Formulary Decisions
Search for the outcome of decisions made by the Formulary Committee
Adalimumab
Adalimumab
Routinely available
NICE (TA455 (SMC 1068/15))
04/12/2024
Indication
Treatment of severe chronic plaque psoriasis in children and adolescents from 4 years of age who have had an inadequate response to or are inappropriate candidates for topical therapy and phototherapies.
Therapeutic Area
Skin
Status Description
Routinely available in line with national guidance
Formulation
-
Comments
Refer to pathway or local board guidelines for preferred formulation
Link to Advice
Advice Published
12/07/2017